After discussion with several large institutional investment funds, investment bankers and research analysts, it is clear that there are certain requirements that the larger, more seasoned investment community would like to see when an issuer within the development-stage biotechnology space presents itself to the mature capital markets in the United States:

The Company must have adequate authorized shares available to raise additional capital to fund ongoing operations, if necessary;
The Company must have sufficient authorized shares available to complete mergers & acquisitions in the event attractive, synergistic opportunities presents themselves in a time-sensitive environment due to market conditions;
The Company must have sufficient shares available in its option pool to be able to recruit the best talent to lead its programs;
The Company must have sufficient shares available to defend itself from unwanted or ill-timed hostile takeover activity, as a negotiating tool to maximize shareholder value.
- See more at: http://www.thechairmansblog.com/amarantus-bio...zlzFT.dpuf